Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-2: Olverembatinib vs Bosutinib in Chronic Phase CML
jRCT2051260072Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of olverembatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Ascentage Pharma. Primary endpoints: MMR rate Part A and MMR rate Part B. Started Jun 2026; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2051260072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260072.